欧洲呼吸学会住院成人COVID-19管理动态指南
欧洲呼吸学会工作组采用GRADE方法制定住院成人COVID-19管理动态指南,基于截至2021年2月20日的证据。强推荐使用全身性糖皮质激素和抗凝治疗,条件性推荐IL-6受体拮抗剂及经鼻高流量氧疗或无创通气,强推荐反对使用羟氯喹和洛匹那韦-利托那韦。
要点
- 需补充氧或通气支持的住院COVID-19患者,强推荐使用全身性糖皮质激素。
- 住院COVID-19患者强推荐使用抗凝治疗。
- 低氧性呼吸衰竭患者条件性推荐IL-6受体拮抗剂及经鼻高流量氧疗或无创通气。
核心结论
- 现有证据支持对特定干预措施作出强推荐或反对的推荐。
- 指南将随着新证据出现定期更新。
研究设计与样本
- 欧洲呼吸学会工作组制定、中国胸科学会认可的动态指南。
- 采用PICO格式确定优先干预措施,使用GRADE方法评估证据质量和推荐强度。
- 进行了系统文献综述,并在可能时通过荟萃分析汇总数据。
主要发现
- 强推荐在需要补充氧或通气支持的患者中使用全身性糖皮质激素。
- 强推荐住院患者使用抗凝治疗。
- 条件性推荐低氧性呼吸衰竭患者使用IL-6受体拮抗剂单克隆抗体治疗及经鼻高流量氧疗或无创通气。
- 强推荐反对使用羟氯喹和洛匹那韦-利托那韦。
- 条件性推荐反对使用阿奇霉素、羟氯喹联合阿奇霉素、秋水仙碱及瑞德西韦(后者特指需要有创机械通气的患者)。
关键数值与推荐
- 强推荐:需要补充氧或通气支持的患者使用全身性糖皮质激素。
- 强推荐:住院患者使用抗凝治疗。
- 条件性推荐:低氧性呼吸衰竭患者使用IL-6受体拮抗剂及经鼻高流量氧疗或无创通气。
- 强推荐反对:使用羟氯喹和洛匹那韦-利托那韦。
- 条件性推荐反对:使用阿奇霉素、羟氯喹联合阿奇霉素、秋水仙碱及瑞德西韦(特指需要有创机械通气的患者)。
临床怎么用
- 对需要补充氧或通气支持的住院COVID-19患者应使用全身性糖皮质激素。
- 对住院COVID-19患者应使用抗凝治疗。
- 对低氧性呼吸衰竭患者可考虑IL-6受体拮抗剂及经鼻高流量氧疗或无创通气。
- 不应使用羟氯喹、洛匹那韦-利托那韦、阿奇霉素、羟氯喹联合阿奇霉素、秋水仙碱。
- 对需要有创机械通气的患者不应使用瑞德西韦;对需要补充氧的患者未作推荐。
局限性
- 证据截止于2021年2月20日。
- 对需要补充氧的患者未对瑞德西韦作出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of SARS-CoV-2 infection have a high mortality rate and frequently require noninvasive respiratory support or invasive ventilation. Optimising and standardising management through evidence-based guidelines may improve quality of care and therefore patient outcomes. METHODS: A task force from the European Respiratory Society and endorsed by the Chinese Thoracic Society identified priority interventions (pharmacological and non-pharmacological) for the initial version of this "living guideline" using the PICO (population, intervention, comparator, outcome) format. The GRADE approach was used for assessing the quality of evidence and strength of recommendations. Systematic literature reviews were performed, and data pooled by meta-analysis where possible. Evidence tables were presented and evidence to decision frameworks were used to formulate recommendations. RESULTS: Based on the available evidence at the time of guideline development (20 February, 2021), the panel makes a strong recommendation in favour of the use of systemic corticosteroids in patients requiring supplementary oxygen or ventilatory support, and for the use of anticoagulation in hospitalised patients. The panel makes a conditional recommendation for interleukin (IL)-6 receptor antagonist monoclonal antibody treatment and high-flow nasal oxygen or continuous positive airway pressure in patients with hypoxaemic respiratory failure. The panel make strong recommendations against the use of hydroxychloroquine and lopinavir-ritonavir. Conditional recommendations are made against the use of azithromycin, hydroxychloroquine combined with azithromycin, colchicine, and remdesivir, in the latter case specifically in patients requiring invasive mechanical ventilation. No recommendation was made for remdesivir in patients requiring supplemental oxygen. Further recommendations for research are made. CONCLUSION: The evidence base for management of COVID-19 now supports strong recommendations in favour and against specific interventions. These guidelines will be regularly updated as further evidence becomes available.
引用
- Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021. PMID: 33692120. doi:10.1183/13993003.00048-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。